Eli Lilly considers copying Novo Nordisk's semaglutide branding strategy

Novo Nordisk branded the GLP-1 analog, semaglutide, under different names for respective treatments of obesity and diabetes. Now, Eli Lilly is chewing over a similar move for tirzepatide.
Photo: Novo Nordisk & Ritzau Scanpix/Reuters/Vincent Kessler
Photo: Novo Nordisk & Ritzau Scanpix/Reuters/Vincent Kessler
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Novo Nordisk has a history of marketing drugs under different names for treatments of obesity and diabetes, respectively. Novo Nordisk's biggest competitor, Eli Lilly, is now pondering a similar move, writes industry media Fiercepharma.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading